Patents by Inventor Craig Rosen

Craig Rosen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 9416185
    Abstract: Disclosed are humanized antibodies that bind specifically to TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.
    Type: Grant
    Filed: April 3, 2014
    Date of Patent: August 16, 2016
    Assignee: TEVA BIOPHARMACEUTICALS USA, INC.
    Inventors: Rodger Smith, Palanisamy Kanakaraj, Viktor Roschke, Craig Rosen, Bridget A. Cooksey
  • Patent number: 9403905
    Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.
    Type: Grant
    Filed: May 15, 2014
    Date of Patent: August 2, 2016
    Assignee: HUMAN GENOME SCIENCES, INC.
    Inventors: Craig Rosen, Vivian Albert, Steven M. Ruben, Ruth Wager
  • Publication number: 20140342405
    Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.
    Type: Application
    Filed: May 15, 2014
    Publication date: November 20, 2014
    Applicant: Human Genome Sciences, Inc.
    Inventors: Craig Rosen, Vivian Albert, Steven M. Ruben, Ruth Wager
  • Publication number: 20140315250
    Abstract: Disclosed are humanized antibodies that bind specifically to TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.
    Type: Application
    Filed: April 3, 2014
    Publication date: October 23, 2014
    Applicant: TEVA Biopharmaceuticals USA, Inc.
    Inventors: Rodger SMITH, Palanisamy Kanakaraj, Viktor Roschke, Craig Rosen, Bridget A. Cooksey
  • Patent number: 8784809
    Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.
    Type: Grant
    Filed: January 24, 2013
    Date of Patent: July 22, 2014
    Assignee: Human Genome Sciences, Inc.
    Inventors: Craig Rosen, Vivian Albert, Steven M. Ruben, Ruth Wager
  • Patent number: 8728482
    Abstract: Disclosed are humanized antibodies that bind specifically to TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.
    Type: Grant
    Filed: August 14, 2012
    Date of Patent: May 20, 2014
    Assignee: TEVA Biopharmaceuticals USA, Inc.
    Inventors: Rodger Smith, Palanisamy Kanakaraj, Viktor Roschke, Craig Rosen, Bridget A. Cooksey
  • Publication number: 20130323240
    Abstract: The present invention is directed to antigen-binding polypeptides, or variants or derivatives thereof which specifically bind the LIGHT polypeptide. The invention is also directed to methods of making and using such antibodies specifically in the treatment or diagnosis of immune, inflammatory and malignant diseases or conditions (e.g. inflammatory bowel disease; Crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis and transplantation).
    Type: Application
    Filed: August 8, 2013
    Publication date: December 5, 2013
    Applicant: TEVA Biopharmaceuticals USA, Inc.
    Inventors: Rodger Smith, Palanisamy Kanakaraj, Bridget A. Cooksey, Viktor Roschke, Craig Rosen
  • Publication number: 20130309232
    Abstract: Disclosed are human VEGF-2 antibodies, antibody fragments, or variants thereof. Also provided are processes for producing such antibodies. The present invention relates to methods and compositions for preventing, treating or ameliorating a disease or disorder comprising administering to an animal, preferably a human, an effective amount of one or more VEGF-2 antibodies or fragments or variants thereof.
    Type: Application
    Filed: January 24, 2013
    Publication date: November 21, 2013
    Applicant: HUMAN GENOME SCIENCES, INC.
    Inventors: Craig Rosen, Vivian Albert, Steven M. Ruben, Ruth Wager
  • Publication number: 20130253979
    Abstract: A computer implemented method for managing risk, which can include determining an organizational impact score from an aggregate of scenario impact scores and storing the organizational impact score in a memory of the computer. Some embodiments include calculating a likelihood score based upon an analysis of threats, imminence of each threat, and a likelihood associated with each threat, and storing the likelihood score in a memory of the computer. In some embodiments, an organizational maturity score is determined based on the ability of the organization to mitigate the actions of a potential threat and recover from a given scenario, and the organizational maturity score is stored in a memory of the computer. Some embodiments include calculating a Risk Index using a processor of the computer wherein the Risk Index equals the impact score multiplied by the likelihood score and divided by the maturity score.
    Type: Application
    Filed: March 13, 2013
    Publication date: September 26, 2013
    Applicant: Pacific Gas and Electric Company
    Inventors: Ramsey Williams, James Sample, Craig Rosen, Suneel Sundar, Richard Jones, Eddie Borrero
  • Patent number: 8524869
    Abstract: The present invention is directed to antigen-binding polypeptides, or variants or derivatives thereof which specifically bind the LIGHT polypeptide. The invention is also directed to methods of making and using such antibodies specifically in the treatment or diagnosis of immune, inflammatory and malignant diseases or conditions (e.g. inflammatory bowel disease; Crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis and transplantation).
    Type: Grant
    Filed: March 22, 2010
    Date of Patent: September 3, 2013
    Assignee: Teva Biopharmaceuticals USA, Inc.
    Inventors: Rodger Smith, Palanisamy Kanakaraj, Bridget A. Cooksey, Viktor Roschke, Craig Rosen
  • Publication number: 20120308480
    Abstract: Disclosed are humanized antibodies that bind specifically to TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.
    Type: Application
    Filed: August 14, 2012
    Publication date: December 6, 2012
    Inventors: Rodger Smith, Palanisamy Kanakaraj, Viktor Roschke, Craig Rosen, Bridget A. Cooksey
  • Patent number: 8263743
    Abstract: Disclosed are humanized antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.
    Type: Grant
    Filed: November 13, 2008
    Date of Patent: September 11, 2012
    Assignee: Teva Biopharmaceuticals USA, Inc.
    Inventors: Rodger Smith, Palanisamy Kanakaraj, Viktor Roschke, Craig Rosen, Bridget A. Cooksey
  • Publication number: 20120100074
    Abstract: The present invention is directed to antigen-binding polypeptides, or variants or derivatives thereof which specifically bind the LIGHT polypeptide. The invention is also directed to methods of making and using such antibodies specifically in the treatment or diagnosis of immune, inflammatory and malignant diseases or conditions (e.g. inflammatory bowel disease; Crohn's disease, ulcerative colitis, multiple sclerosis, rheumatoid arthritis and transplantation).
    Type: Application
    Filed: March 22, 2010
    Publication date: April 26, 2012
    Inventors: Rodger Smith, Palanisamy Kanakaraj, Bridget A. Cooksey, Viktor Roschke, Craig Rosen
  • Publication number: 20100143360
    Abstract: Disclosed is a human VEGF2 polypeptide and DNA(RNA) encoding such VEGF2 polypeptides. Also provided is a procedure for producing such polypeptide by recombinant techniques and antibodies and antagonist against such polypeptide. Also disclosed is a method of using such polypeptide for stimulating wound healing and for vascular tissue repair. Also provided are methods of using the antagonists to inhibit tumor growth, inflammation and to treat diabetic retinopathy, rheumatoid arthritis and psoriasis. Diagnostic methods for detecting mutations in the VEGF2 coding sequence and alterations in the concentration of VEGF2 protein in a sample derived from a host are also disclosed.
    Type: Application
    Filed: October 24, 2008
    Publication date: June 10, 2010
    Applicant: HUMAN GENOME SCIENCES, INC.
    Inventors: Craig Rosen, Jing-Shan Hu, Liang Cao
  • Publication number: 20090280116
    Abstract: Disclosed are humanized antibodies that bind specifically to the receptor TNF superfamily member 15 (TNFSF15), also known as TL1A. Methods of making and using the anti-TL1A antibodies are also described. The humanized antibodies may be antagonists and may used to treat or diagnose conditions associated with TL1A function.
    Type: Application
    Filed: November 13, 2008
    Publication date: November 12, 2009
    Inventors: Rodger SMITH, Palanisamy KANAKARAJ, Viktor ROSCHKE, Craig ROSEN
  • Publication number: 20080226586
    Abstract: The present invention concerns a member of the human chemokine CC protein family. In particular, isolated nucleic acid molecules are provided encoding the chemokine ?-15 protein. Chemokine ?-15 polypeptides are also provided. The invention further concerns diagnostic methods for detecting thymus disorders and therapeutic methods for modulating bone marrow cell proliferation and differentiation.
    Type: Application
    Filed: October 2, 2006
    Publication date: September 18, 2008
    Applicant: Human Genome Sciences, Inc.
    Inventors: Ying-Fei Wei, Brent Kreider, Craig Rosen
  • Publication number: 20080163647
    Abstract: A jewelry arrangement having a mounting, a main gemstone positioned in the mounting, and a plurality of secondary gemstone positioned in the mounting underneath the main gemstone. The main gemstone can have a crown with a table and a pavilion, wherein the table can be positioned adjacent and at a first distance from the plurality of secondary gemstones. The main gemstone can also have a plurality of side which converge toward each other and have a plurality of facets. The sides can coverage towards a top which can be a second distance from the secondary gemstones such that the first distance is less than the second distance. An optical illusion can be created by orienting a main gemstone above a first number of secondary gemstones and configuring the main gemstone so that when the secondary gemstones are viewed through the main gemstone, a second number of secondary gemstones is visible such that the second number is greater than the first number.
    Type: Application
    Filed: January 5, 2007
    Publication date: July 10, 2008
    Inventor: Ronald Craig Rosen
  • Publication number: 20080103090
    Abstract: The present invention relates to human secreted polypeptides, and isolated nucleic acid molecules encoding said polypeptides, useful for diagnosing and treating cancer and other hyperproliferative diseases and disorders. Antibodies that bind these polypeptides are also encompassed by the present invention. Also encompassed by the invention are vectors, host cells, and recombinant and synthetic methods for producing said polynucleotides, polypeptides, and/or antibodies. The invention further encompasses screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The present invention further encompasses methods and compositions for inhibiting or enhancing the production and function of the polypeptides of the present invention.
    Type: Application
    Filed: March 19, 2007
    Publication date: May 1, 2008
    Applicant: Human Genome Sciences, Inc.
    Inventors: Craig Rosen, Steven Ruben
  • Publication number: 20080058247
    Abstract: Receptor polypeptides and polynucleotides and methods for producing such polypeptides by recombinant techniques are disclosed. Also disclosed are methods for utilizing receptor polypeptides and polynucleotides in the design of protocols for the treatment of diseases and diagnostic assays for such conditions.
    Type: Application
    Filed: August 1, 2007
    Publication date: March 6, 2008
    Applicant: Human Genome Sciences, Inc.
    Inventors: Jian Ni, Craig Rosen, Reiner Gentz
  • Publication number: 20080057004
    Abstract: Disclosed are fusion proteins that include albumin fused to a polypeptide that has insulin activity. The fusion proteins may include albumin fused to insulin or an insulin analog. In particular, the fusions proteins may include albumin fused to a single chain insulin analog. The fusion proteins may exhibit extended insulin activity in vivo or in vitro relative to insulin that is not fused to albumin. The fusion proteins may be formulated as aerosol compositions.
    Type: Application
    Filed: August 7, 2007
    Publication date: March 6, 2008
    Inventors: Adam Bell, Craig Rosen, Indrajit Sanyal, Qinghai Zhao